Tegafur-uracil

Generic Name: Tegafur-uracil

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₃FN_₄O_₅

CAS Number: 74578-38-4

Unique Ingredient Identifier: HMI5GR78FR

Background: Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd. It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.

Indication: Tegafur-uracil is indicated for the first line treatment of metastatic colorectal cancer with concomitant administration of calcium folinate. Colorectal cancer is the third most diagnosed cancer and 30% of the cases can present the metastatic state.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Datopotamab Deruxtecan
Drug: Carboplatin
Drug: Rilvegostomig
Drug: Cisplatin
Drug: Etoposide
Drug: Pemetrexed
Drug: Vinorelbine
Drug: UFT

First Posted Date: 2024-08-21

Last Posted Date: 2024-12-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 660

Registration Number: NCT06564844

Locations: 🇻🇳
Research Site, Vinh, Vietnam

Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+

Phase 2

Conditions: Squamous Cell Carcinoma of Oral Cavity

Interventions: Drug: tegafur-uracil

First Posted Date: 2017-04-20

Last Posted Date: 2019-02-12

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 68

Registration Number: NCT03121313

Locations: 🇨🇳
Chang-Gung Memorial Hospital-LinKou, Taoyuan City, Taiwan

The Maintenance Treatment of UFT in Advanced Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: UFT

First Posted Date: 2016-09-16

Last Posted Date: 2016-10-12

Lead Sponsor: Fudan University

Target Recruit Count: 58

Registration Number: NCT02903498

A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer

Phase 4

Conditions: MSI-L/MSS
Stage II Colon Cancer

Interventions: Drug: tegafur-uracil

First Posted Date: 2016-09-02

Last Posted Date: 2016-09-07

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 300

Registration Number: NCT02887365

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection

Not Applicable

Conditions: Stage III Colon Cancer

Interventions: Drug: tegafur-uracil

First Posted Date: 2016-07-19

Last Posted Date: 2017-02-08

Lead Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital

Target Recruit Count: 400

Registration Number: NCT02836977

Locations: 🇨🇳
Chung-Ho Memorial Hospital, Kaohsiung Medical University:, Kaohsiung, Taiwan

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

Phase 2

Completed

Conditions: Vascular Endothelial Growth Factor Overexpression
Adult Hepatocellular Carcinoma
Recurrent Hepatocellular Carcinoma
Adverse Reaction to Drug

Interventions: Drug: thalidomine
Drug: tegafur-uracil

First Posted Date: 2015-05-19

Last Posted Date: 2017-02-07

Lead Sponsor: Chang Gung Memorial Hospital

Target Recruit Count: 40

Registration Number: NCT02447679

Locations: 🇨🇳
Chang Gung Memorial Hospital, Taoyuan, Taiwan

Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Cetuximab
Drug: Irinotecan
Drug: Oxaliplatin
Drug: UFT

First Posted Date: 2010-10-21

Last Posted Date: 2014-06-11

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 47

Registration Number: NCT01225744

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧
North Wales Cancer Treatment Centre, Llansantffraid Glan Conwy, United Kingdom
🇬🇧
The Royal Marsden, London and Surrey, United Kingdom

Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma

Phase 2

Conditions: Head and Neck Cancer

Interventions: Drug: tegafur-uracil

First Posted Date: 2009-03-05

Last Posted Date: 2011-07-26

Lead Sponsor: Mackay Memorial Hospital

Target Recruit Count: 115

Registration Number: NCT00855881

Locations: 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan

Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: tegafur-gimeracil-oteracil potassium
Drug: folinate calcium
Drug: tegafur-uracil

First Posted Date: 2008-04-17

Last Posted Date: 2016-08-03

Lead Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Target Recruit Count: 1535

Registration Number: NCT00660894

Locations: 🇯🇵
Tokyo Medical and Dental University, Tokyo, Japan

UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Thalidomide
Drug: Tegafur/Uracil

First Posted Date: 2007-08-23

Last Posted Date: 2011-10-17

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 44

Registration Number: NCT00519688

Locations: 🇨🇳
Department of Oncology , National Taiwan University Hospital, Taipei, Taiwan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy